TransMedics (TMDX) Reports Q3 Earnings: What Key Metrics Have to Say

Zacks10-30

TransMedics (TMDX) reported $108.76 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 63.7%. EPS of $0.12 for the same period compares to -$0.12 a year...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2479879737?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/UPInF06X6fJkTqeimnpZuQ--~B/aD03NDU7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/078b2d95159d12a337f09f2519ff10ba","is_english":true,"pubTime":"2024-10-30 21:30","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2479879737","market":"us","top_or_hot":-1,"title":"TransMedics (TMDX) Reports Q3 Earnings: What Key Metrics Have to Say","media":"Zacks","content":"<div>\n<p>TransMedics (TMDX) reported $108.76 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 63.7%. EPS of $0.12 for the same period compares to -$0.12 a year...</p>\n\n<a href=\"https://finance.yahoo.com/news/transmedics-tmdx-reports-q3-earnings-133045397.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TransMedics (TMDX) Reports Q3 Earnings: What Key Metrics Have to Say</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTransMedics (TMDX) Reports Q3 Earnings: What Key Metrics Have to Say\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-30 21:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/transmedics-tmdx-reports-q3-earnings-133045397.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>TransMedics (TMDX) reported $108.76 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 63.7%. EPS of $0.12 for the same period compares to -$0.12 a year...</p>\n\n<a href=\"https://finance.yahoo.com/news/transmedics-tmdx-reports-q3-earnings-133045397.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TMDX","symbol_name":"TransMedics Group Inc.","start_time":0,"source_url":"https://finance.yahoo.com/news/transmedics-tmdx-reports-q3-earnings-133045397.html","article_id":"2479879737","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/UPInF06X6fJkTqeimnpZuQ--~B/aD03NDU7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/078b2d95159d12a337f09f2519ff10ba"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2479879737","pubTimestamp":1730295045,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"TransMedics  reported $108.76 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 63.7%. EPS of $0.12 for the same period compares to -$0.12 a year ago.The reported revenue represents a surprise of -4.78% over the Zacks Consensus Estimate of $114.22 million. With the consensus EPS estimate being $0.28, the EPS surprise was -57.14%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.Here is how TransMedics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:. Shares of TransMedics have returned -38.9% over the past month versus the Zacks S&P 500 composite's +1.8% change. The stock currently has a Zacks Rank #3 , indicating that it could perform in line with the broader market in the near ","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"TMDX":"TransMedics Group Inc."},"translate_title":"TransMedics(TMDX)报告第三季度收益：关键指标说明了什么","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TMDX":1},"content_text":"TransMedics (TMDX) reported $108.76 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 63.7%. EPS of $0.12 for the same period compares to -$0.12 a year ago.\nThe reported revenue represents a surprise of -4.78% over the Zacks Consensus Estimate of $114.22 million. With the consensus EPS estimate being $0.28, the EPS surprise was -57.14%.\nWhile investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.\nSince these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.\nHere is how TransMedics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: \n\nGeographic Revenues- United States: $104.92 million versus $108.65 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +75.8% change.\nGeographic Revenues- All other countries: $2.58 million versus the four-analyst average estimate of $4.03 million. The reported number represents a year-over-year change of -39.9%.\nNet revenue by OCS product- OCS Lung net revenue: $3.91 million versus the four-analyst average estimate of $4.71 million. The reported number represents a year-over-year change of +5.1%.\nNet revenue by OCS product- OCS Liver net revenue: $76.67 million versus the four-analyst average estimate of $77.47 million. The reported number represents a year-over-year change of +85.6%.\nNet revenue by OCS product- OCS Heart net revenue: $26.93 million versus the four-analyst average estimate of $30.50 million. The reported number represents a year-over-year change of +42%.\n View all Key Company Metrics for TransMedics here>>>\n\nShares of TransMedics have returned -38.9% over the past month versus the Zacks S&P 500 composite's +1.8% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.\n\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nTransMedics Group, Inc. (TMDX) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2479879737"}